InflaRx (IFRX) Non Operating Interest Expenses (2017 - 2018)
InflaRx (IFRX) posted Non Operating Interest Expenses of -$512940.0 for Q3 2018, up 80.37% sequentially from -$2.6 million in Q2 2018, and up 48.58% YoY from -$345218.7 in Q3 2017.
InflaRx (IFRX) Non Operating Interest Expenses (2017 - 2018) Analysis & Trends
InflaRx has reported Non Operating Interest Expenses for 2 years, with the latest figure at -$512940.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | -17,020.46 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -512,939.97 |
| Jun 30, 2018 | -2.61 Mn |
| Sep 30, 2017 | -997,628.71 |
| Jun 30, 2017 | -926,920.08 |